对于业绩变动，驱动力解释称，主要是由于报告期内毛利较高的造血系列1、2产品销售占比下降约18.45%，毛利较低的造血系列3产品销售占比上升约 17.09%，导致综合毛利率同比下降约9.87%，营业毛利润同比减少约542.24万元。 此外，上期公司收回大额坏账，信用减值损失科目表现为大额收益，本期信用减值损失同比负方向变动约251.62万元； 本期中介机构服务费、管理人员薪 酬、固定资产及使用权资产折旧等管理费用同比增加约130.87万元；本期对联营企业的投资收益同比减少约109.82万元。 报告期末，公司总资产预计为2.42亿元，同比减少1.87%；归属于市公司股东的所有者权益预计为2.33亿元，同比减少2.10%。 公开资料显示，广东驱动力生物科技集团股份有限公司成立于2012年，2021年在北交所上市，公司是一家专业从事动物造血营养的国家高新技术企业。旗 下拥有广东三行生物科技有限公司、广州三行饲料有限公司、广州赛桃花生物科技有限公司、造血营养研究院等机构。 2月26日晚间，驱动力（920275）公告，2025年营业收入7680.92万元，同比增长7.07%；净利润455.36万元，同比下降67.42%。 ...

广东驱动力生物科技集团股份有限公司 证券代码：920275 证券简称：驱动力 公告编号：2026-004 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年 年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 76,809,154.15 | 71,736,730.76 | 7.07% | | 利润总额 | 4,648,346.78 | 15,149,444.36 | -69.32% | | 归属于上市公司股 | 4,553,599.67 | 13,976,825.22 | -67.42% | | 东的净利润 | | | | | 归属于上市公司股 东的扣除非经常性 | 4,434,47 ...

Core Viewpoint - The animal health sector experienced a rise of 1.15% on February 3, with *ST Green康 leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Individual Stock Performance - *ST Green康 (002868) closed at 36.70, with a gain of 3.29% and a trading volume of 11,000 lots, amounting to 39.61 million yuan [1]. - 回盛生物 (300871) closed at 28.30, up by 2.83%, with a trading volume of 166,400 lots and a turnover of 467 million yuan [1]. - 大禹生物 (920970) closed at 8.14, increasing by 2.13%, with a trading volume of 23,300 lots and a turnover of 18.92 million yuan [1]. - 普莱柯 (603566) closed at 14.00, up by 2.04%, with a trading volume of 66,100 lots and a turnover of 91.87 million yuan [1]. - 驱动力 (920275) closed at 9.15, increasing by 1.78%, with a trading volume of 14,900 lots and a turnover of 13.61 million yuan [1]. - 永顺生物 (920729) closed at 9.43, up by 1.73%, with a trading volume of 52,100 lots and a turnover of 48.48 million yuan [1]. - 科前生物 (688526) closed at 16.18, increasing by 1.25%, with a trading volume of 29,000 lots and a turnover of 46.60 million yuan [1]. - 申联生物 (688098) closed at 9.45, up by 0.96%, with a trading volume of 29,700 lots and a turnover of 27.90 million yuan [1]. - 生物股份 (600201) closed at 16.42, increasing by 0.86%, with a trading volume of 400,700 lots and a turnover of 655 million yuan [1]. - 瑞普生物 (300119) closed at 19.16, up by 0.63%, with a trading volume of 60,400 lots and a turnover of 115 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net outflow of 155 million yuan from institutional investors, while retail investors contributed a net inflow of 119 million yuan [2]. - The main capital flow data indicates that 中牧股份 (600195) had a net inflow of 5.91 million yuan from institutional investors [3]. - 普莱柯 (603566) experienced a net inflow of 5.90 million yuan from institutional investors, while retail investors had a net outflow of 12.09 million yuan [3]. - *ST Green康 (002868) had a net inflow of 2.82 million yuan from institutional investors, with retail investors contributing a net inflow of 2.25 million yuan [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].

证券代码：920275 证券简称：驱动力 公告编号：2026-003 广东驱动力生物科技集团股份有限公司 2025 年年度业绩预告公告 单位：万元 | 项目 | | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | --- | | 归属于上市 | 公司 | 350.00～550.00 | 1,397.68 | -74.96%～-60.65% | | 股东的净利润 | | | | | 二、本期业绩重大变化的主要原因 报告期内毛利较高的造血系列 1、2 产品销售占比下降，毛利较低的造血系 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、本期业绩预告情况 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 (二)业绩预告情况 √年度实现盈利，且净利润与上年 ...

证券代码：920275 证券简称：驱动力 公告编号：2026-001 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 日常性关联交易预计情况 （一） 预计情况 单位：元 | 关联交易类别 | 主要交易内容 | 预计 2026 | 年 | 2025 | 年与关联方 | 预计金额与上年实际发生金 | | --- | --- | --- | --- | --- | --- | --- | | | | 发生金额 | | | 实际发生金额 | 额差异较大的原因 | | 购买原材料、 | | | | | | 2025年预计关联方交易额200 万元，下半年因关联方供应商 | | 燃料和动力、 | 原材料采购 | 1,500,000 | | | 989,350 | 供应量不足，本公司从其他供 | | 接受劳务 | | | | | | 应商补货，导致关联交易实际 | | | | | | | | 发生额低于预期。 | | 销售产品、商 | | | | | | | | 品、提供劳务 | | | | | | | | 委托关 ...

已披露的公开承诺事项均正常履行，不存在超期未履行完毕及违反承诺的情形，离 任后将继续履行相关承诺。承诺内容详见 2021 年公司向不特定合格投资者公开发行股 票并在北京证券交易所上市的《公开发行股票说明书》之"第四节发行人基本情况"之 "九、重要承诺"。 二、合规性说明及影响 （一）人员变动的合规性说明 陆应诚先生离任符合相关法律法规、部门规章、业务规则和公司章程等规定，未导 致公司董事会成员人数低于法定最低人数，未导致董事会中兼任高级管理人员的董事和 由职工代表担任的董事人数超过公司董事总数的二分之一，未导致董事会或者其专门委 员会中独立董事所占的比例不符合相关规则或者公司章程的规定，未导致独立董事中欠 缺会计专业人士。 （二）人员变动对公司的影响 证券代码：920275 证券简称：驱动力 公告编号：2026-002 广东驱动力生物科技集团股份有限公司 高级管理人员离任公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、高级管理人员离任的基本情况 本公司陆应诚先生，因到龄退休，自 2026 年 1 ...

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on January 28, with Yongshun Biological leading the drop, while the overall market indices showed minor gains [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up by 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up by 0.09% [1]. - The animal health sector's performance is summarized in a table showing individual stock movements, with notable gainers including Biological Shares and Jinhai Biological, which rose by 1.51% and 1.49% respectively [1]. Group 2: Stock Performance - Yongshun Biological saw a significant decline of 7.49%, closing at 10.13, with a trading volume of 141,500 shares and a turnover of 145 million yuan [2]. - Other notable decliners included Shoufeng Holdings and Haili Biological, which fell by 2.21% and 2.08% respectively [2]. - The trading volume and turnover for various stocks in the animal health sector are detailed, indicating varied investor interest [2]. Group 3: Capital Flow - The animal health sector experienced a net inflow of 18.02 million yuan from institutional investors, while retail investors saw a net inflow of 9.33 million yuan [2]. - However, there was a net outflow of 27.35 million yuan from speculative funds, indicating a mixed sentiment among different investor types [2]. - A detailed table shows the net capital flow for individual stocks, highlighting significant movements in and out of various companies [3].

Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]

Core Viewpoint - The animal health sector experienced a slight increase of 0.54% on January 22, with Xianfeng Holdings leading the gains. The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the Shenzhen Component Index increased by 0.5% to 14327.05 [1]. Group 1: Stock Performance - Xianfeng Holdings (002141) closed at 4.19, up 9.97% with a trading volume of 720,300 shares and a transaction value of 297 million yuan [1]. - Other notable performers include Biological Shares (600201) at 17.60, up 1.79%, and Zhongmu Shares (600195) at 8.54, also up 1.79% [1]. - The overall trading volume and transaction values for various stocks in the animal health sector indicate active market participation [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 73.79 million yuan from institutional investors, while retail investors experienced a net outflow of 27.83 million yuan [2]. - The main capital inflow was primarily directed towards Xianfeng Holdings, which attracted 121 million yuan from institutional investors, representing 40.71% of its trading volume [3]. - Other stocks like Jinhe Biological (002688) and *ST Green Health (002868) also saw varying degrees of net inflow and outflow from different investor categories [3].